Interleukin 6 Pathway Inhibitors

Interleukin 6 (IL-6) inhibitors block a cytokine that drives joint inflammation, acute phase response, fever and anaemia of chronic disease.

Tocilizumab and sarilumab block the IL-6 receptor; siltuximab binds IL-6 itself. They treat rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis, cytokine release syndrome and, for some agents, severe COVID-19 and Castleman disease. They work as monotherapy when methotrexate cannot be used.

Mechanism. Receptor blockade stops IL-6 signalling through both membrane and soluble receptors, which lowers C-reactive protein within days, reduces B cell activation and hepcidin, and raises haemoglobin.

Pharmacokinetics. Monoclonal antibodies cleared by receptor-mediated and proteolytic routes. Tocilizumab half-life is dose dependent, about 11 to 13 days at steady state; clearance rises with high body weight.

Practical points. Biosimilar tocilizumab exists. Dose reduction or interval extension is used in remission. Hold treatment when neutrophils, platelets or transaminases cross the safety limits listed under contraindications.

• First-line. Giant cell arteritis (relapsing disease or steroid sparing); systemic juvenile idiopathic arthritis; cytokine release syndrome after CAR-T cell therapy.
• Alternative. Rheumatoid arthritis after csDMARD and TNF inhibitor failure, or when methotrexate cannot be used; Still disease; polymyalgia rheumatica.
• Specialist. Takayasu arteritis, systemic sclerosis lung disease, Castleman disease, severe COVID-19 with hypoxia and raised inflammatory markers (with glucocorticoid).
• Emergency. Cytokine release syndrome; macrophage activation syndrome in selected cases.

Selection. Prefer IL-6 inhibition when monotherapy is needed. Remember that C-reactive protein and fever are suppressed, so serious infection can be missed.

Contraindications. Active serious infection; untreated tuberculosis or hepatitis B; hypersensitivity; neutrophils under 0.5 x 10^9/L; platelets under 50 x 10^9/L; transaminases over 5 times the upper limit; active diverticulitis or bowel perforation risk.

Serious adverse effects.

• Serious infection including tuberculosis, with muted fever and C-reactive protein.
• Neutropenia, thrombocytopenia, raised transaminases and raised lipids.
• Gastrointestinal perforation, mainly in diverticular disease or with glucocorticoids and NSAIDs.
• Infusion and injection-site reactions; rare demyelination.

Major interactions. Live vaccines; other biologics; CYP3A4 substrates with narrow range (simvastatin, ciclosporin, warfarin) whose levels fall as inflammation settles; NSAIDs and glucocorticoids raise perforation risk.

Common prescribing errors.

• Using C-reactive protein to judge infection during treatment.
• Skipping blood count and liver tests.
• Starting without tuberculosis and hepatitis B screening.
• Using in a patient with diverticulitis.
• Not adjusting statin or anticoagulant doses.

Special groups.

• Pregnancy: limited data; stop unless essential.
• Breastfeeding: avoid or specialist advice.
• Children: weight-based dosing for juvenile arthritis; specialist.
• Older adults: higher infection risk.
• Kidney: no adjustment in mild to moderate impairment.
• Liver: avoid with active liver disease or raised transaminases.
• East Africa: tuberculosis and hepatitis B screening is mandatory; use preventive therapy where indicated; cost limits access, though biosimilars and use in giant cell arteritis may justify the expense.

Monitoring. Neutrophils, platelets and transaminases at 4 to 8 weeks, then every 3 months; lipids at 4 to 8 weeks; infection symptoms at every visit; tuberculosis symptoms yearly.

Referral and escalation. Fever, abdominal pain or suspected perforation; severe infection; neutropenia; transaminases over 3 times the upper limit; pregnancy.

Comparison with alternative classes. IL-6 inhibitors work well alone and treat giant cell arteritis and cytokine release syndrome, which TNF inhibitors do not. They carry more neutropenia, lipid and perforation concerns, and hide infection.